Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia
NCT00161018Phase 3Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2003
- Primary completion
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine and risperidone in schizophrenia (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Efficacy of antipsychotics and Safety of antipsychotics. Started Nov 2003; status: completed.
02
Drugs
quetiapinerisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00161018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161018.